Up to 12 month trends in clinical and biochemical parameters after SGLT2i therapy in patients affected by heart failure patients with reduced ejection fraction
Anno:
2023
Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effects of SGLT2i on some clinical and biochemical parameters as well as the persistence of…